Patients taking Dagliflozin have some protection of the kidneys while lowering the effect of blood glucose, but it can not be used in the end stage of renal function, severely damaged state. Dagliflozin, as a new type of glucose-lowering drug, can inhibit glucose absorption, promote the body’s excess glucose from the kidneys with the urinary excretion, so as to play a role in lowering sugar, but also because of this glucose-lowering mechanism, it can reduce the glomerular perfusion pressure, and the kidneys play a certain protective effect. Patients can use Dagliflozin alone, or can be taken in combination with other glucose-lowering drugs, such as sulfonylureas, insulin, glucosidase inhibitors, etc., but the specific method of taking the drug should be under the guidance of the doctor, according to the patient’s condition individualized. Dagliflozin common adverse reaction is urinary tract infection, mainly due to a large amount of sugar discharged from the urine, triggering the invasion of various types of microorganisms, so that urinary tract infection occurs. Patients taking Dagliflozin should master the indications, only to have a protective effect on the kidneys, under the guidance of the doctor combined with their own condition reasonable choice, not unauthorized use of drugs.